An interventional study of Advanced Cardiac Life Support (ACLS) and Aortic balloon occlusion (ABO) in Cardiac Arrest (CA) and Cardiopulmonary Arrest, sponsored by neurescue. Recruiting at 2 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by neurescue · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Heart Arrest with a site in Germany — 8 open to participants now, 10 under way, none of them phase 3. Heart Arrest · Germany.
Among the 38 studies in Heart Arrest with a site in Germany, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 18 with no phase, and was the 33rd registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →8 of the 38 studies in Heart Arrest with a site in Germany are open now. Recruiting first, the newest first:
Muehlenkreiskliniken, MKK · Sites in Germany
Ages 18+
University Hospital, Ghent · Sites in Germany, Austria, Belgium and 5 more countries
Ages 18+
Lund University · Sites in Germany, Finland, Sweden
Ages 18–100
Leipzig Heart Science gGmbH · Sites in Germany
Ages up to 18
University Hospital Freiburg · Sites in Germany
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 150 across the 23 interventional studies, 200 across the 15 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 38 have an industry lead sponsor. The 10 most frequent:
neurescue is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
neurescue has 4 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Arrest with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT07026773University Hospital, GhentValidity of ICU Clinician's Appraisal of Proportionality in CPR | 2026-12-30 |
| NCT06793033neurescueA Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Support | 2027-01 |
| NCT07607808University Hospital, AachenPsychological Stress and Support Needs of Volunteer First Responders After Smartphone-based Cardiac Arrest Alerts | 2027-05-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies in Heart Arrest with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The NEURESCUE device is the first intelligent balloon catheter for aortic balloon occlusion (ABO), an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment.
The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
The purpose of this study is to compare the clinical safety and performance of Advanced Cardiovascular Life Support (ACLS) versus ACLS in combination with Aortic Balloon Occlusion (ABO) using the NEURESCUE device in subjects with cardiac arrest.
Subjects will be randomized into two arms: ACLS treatment or ACLS + ABO treatment. Those in the ACLS treatment arm will receive standard of care treatment for cardiac arrest, while those in Arm 2 will receive ACLS in combination with ABO.
The NEURESCUE device is an aortic balloon catheter designed to temporarily occlude the aorta. During the treatment, the NEURESCUE Catheter will be placed in the descending aorta and be connected to the NEURESCUE Assistant. The NEURESCUE Assistant facilitates pressure-regulated inflation and deflation of the balloon.
Throughout the treatment, cardiac rhythm and return of spontaneous circulation (ROSC) will be monitored.
The subject will be monitored for a total of 4 visits, where a 90-days follow-up will account for the last visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Enrolled subjects randomized into Arm 1 will receive ACLS treatment.
Procedure: Advanced Cardiac Life Support (ACLS)
Enrolled subjects randomized into Arm 2 will receive ACLS treatment combined with ABO.
Procedure: Advanced Cardiac Life Support (ACLS) · Device: Aortic balloon occlusion (ABO)
Standard of care Advanced Cardiac Life Support (ACLS) consists of cardiopulmonary resuscitation (CPR), airway management, ventilation and defibrillation.
Aortic balloon occlusion (ABO) is a technique that diverts blood flow towards the coronary and cerebral circulation. ABO is investigated as an adjunct to the treatment of cardiac arrest. In this study ABO is performed using the NEURESCUE Catheter, which is inserted through an introducer in the femoral artery, and thereby inserted into the aorta during uninterrupted Advanced Cardiac Life Support (ACLS). The balloon is then temporarily inflated as an adjunct to the treatment of cardiac arrest.
Resuscitation
Subject achieving shockable rhythm or ROSC
Time frame: Measured from 10 minutes after randomization to 70 minutes after randomization
Epinephrine
Dosage of epinephrine administered during resuscitation
Time frame: Measured from 10 minutes after randomization to 70 minutes after randomization
Procedures
Need for any invasive procedures, e.g. surgery, extracorporeal membrane oxygenation (ECMO) or percutaneous coronary intervention (PCI)
Time frame: Measured from 10 minutes after randomization to 90 days post cardiac arrest
(S)A(D)E
All Anticipated (S)AEs/(S)ADEs and Unanticipated (S)AEs/(S)ADEs
Time frame: Measured from randomization to 90 days post cardiac arrest
CPC score
Cerebral Performance Category (CPC) is a five-point scale used to categorize the neurological outcome after cardiac arrest
Time frame: Measured at dischage or at 7 days post cardiac arrest, and 90 days post cardiac arrest
EQ-5D
EQ-5D is a standardized measure of quality of life
Time frame: Measured 90 days post cardiac arrest
Survival
Survival at discharge or 7 day post cardiac arrest (whichever comes first), and survival at 90 days post cardiac arrest
Time frame: Measured at dischage or at 7 days post cardiac arrest, and 90 days post cardiac arrest
Plan to share: No — Individual request
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.
Of 219 interventional studies with no phase under Heart Arrest, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.